Overview

Gynecology Drugs Market is estimated to value over USD 5 billion by 2027 end and register a CAGR of over 5.3% during the forecast period 2020 to 2027.

Gynecological ailments represent a wide range of divergent medical conditions, which are pertaining to the reproductive system of the female body. As a result, gynecological illnesses have a variety of conditions concerning the functioning of the ovaries, uterus and appendages.

There are certain gynecological drugs market trends that are being demonstrated over the past few years. It has been observed that the acceptance of gynecology drugs has been pushing the market. Shifts in the lifestyles of women worldwide has pushed for greater improvements in their healthcare needs. A growing consciousness about good health, nutrition and overall well-being, has contributed to the rise in the demand for innovative gynecological treatments. Such opportunities have created inroads for drug manufacturers to establish better gynecological therapeutics that would deliver positive efficacy as well as minimal side-effects. Moreover, attributes such as revitalized economic growth and a rise in the geriatric female population are projected to boost the gynecology drugs market size.

Segmentation-wise, the market has been fragmented into therapeutics which is bifurcated into hormonal and non-hormonal therapy. The segment for non-hormonal therapy is anticipated to account for the largest market share during the forecast time frame, due to the latest product development, productive qualities in the products, as well as boost in the acceptance of such products. Furthermore, minimal usage of hormonal products owing to the risk of breast cancer has garnered considerable demand for pharmaceutical products that are non-hormonal.

In the case of the indication segment, the market has been categorized based on various conditions ranging from menopausal disorder, gynecology cancers, contraception, gynecology infections, female infertility, polycystic ovary syndrome and others.

Based on the type of distribution channel, the market has been divided into retail, hospital and online pharmacies. Market intelligence has predicted that online pharmacies are shown to prosper at a high CAGR in the forecast time span, since there is a preference for online pharmacies and a boost in the volume of people who use the internet.

Major players that have dominated the market for gynecology drugs includes F. Hoffmann-La Roche Ltd., Sanofi, Amgen Inc., GlaxoSmithKline plc, AstraZeneca, Pfizer, Inc., Lupin Pharmaceuticals, Inc., Eli Lilly and Company, Johnson & Johnson, Bayer AG, Allergan Plc and Merck & Co.

Gynecology Drugs Market

Gynecology Drugs Market Segmentation:

By Therapeutics

Hormonal Therapy

- Estrogen Therapy

- Progestin Therapy

- Combination Therapy

- Thyroid Replacement Therapy

- Parathyroid Hormone Therapy

- Others

Non-hormonal Therapy

- Anti-Infective Agents

- Antineoplastic Agents

- Anti-inflammatory Agents

- Others

By Indication

Gynecology Cancers
Endometriosis
Female Infertility
Menopausal Disorder
Gynecology Infections
Polycystic Ovary Syndrome
Contraception (Birth Control)
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region

North America
Europe
Asia Pacific
Latin America
Middle East & Africa

FutureWise Key Takeaways:

Growth prospects
SWOT analysis
Key trends
Key data-points affecting market growth

Objectives of the Study:

To provide with an exhaustive analysis on the gynecology drugs market by therapeutics, by indication, by distribution channel and by region
To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
To evaluate and forecast micro-markets and the overall market
To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East & Africa
To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions